Literature DB >> 20926578

cis-Acting sequences that contribute to synthesis of minus-strand DNA are not conserved between hepadnaviruses.

Megan L Maguire1, Daniel D Loeb.   

Abstract

Hepadnaviruses are DNA viruses that are found in several mammalian and avian species. These viruses replicate their genome through reverse transcription of an RNA intermediate termed pregenomic RNA (pgRNA). pgRNA is reverse transcribed by the viral polymerase into a minus-strand DNA, followed by synthesis of the plus-strand DNA. There are multiple cis-acting sequences that contribute to the synthesis of minus-strand DNA for human hepatitis B virus (HBV). Less is known about the cis-acting sequences of avian hepadnaviruses that contribute to synthesis of minus-strand DNA. To identify cis-acting sequences of duck hepatitis B virus (DHBV) and heron hepatitis B virus (HHBV), we analyzed variants containing 200-nucleotide (nt) deletions. Most variants of DHBV synthesized minus-strand DNA to 50 to 100% of the wild-type (WT) level, while two variants synthesized less than 50%. For HHBV, most variants synthesized minus-strand DNA to less than 50% the WT level. These results differ from those for HBV, where most of the genome can be removed with little consequence. HBV contains a sequence, φ, that contributes to the synthesis of minus-strand DNA. It has been proposed that DHBV has an analogous sequence. We determined that the proposed φ sequence of DHBV does not contribute to the synthesis of minus-strand DNA. Finally, we found that the DR2 sequence present in all hepadnaviruses is important for synthesis of minus-strand DNA in both DHBV and HHBV but not in HBV. These differences in cis-acting sequences suggest that the individual hepadnaviruses have evolved differences in their mechanisms for synthesizing minus-strand DNA, more so than for other steps in replication.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20926578      PMCID: PMC3004326          DOI: 10.1128/JVI.01487-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  24 in total

1.  cis-Acting sequences that contribute to the synthesis of relaxed-circular DNA of human hepatitis B virus.

Authors:  Ning Liu; Lin Ji; Megan L Maguire; Daniel D Loeb
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

2.  cis-acting sequences required for encapsidation of duck hepatitis B virus pregenomic RNA.

Authors:  R C Hirsch; D D Loeb; J R Pollack; D Ganem
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

3.  Specific requirements for elements of the 5' and 3' terminal regions in flavivirus RNA synthesis and viral replication.

Authors:  Li Yu; Masako Nomaguchi; R Padmanabhan; Lewis Markoff
Journal:  Virology       Date:  2008-01-29       Impact factor: 3.616

4.  A cis-acting element within the 5' leader of a cytomegalovirus beta transcript determines kinetic class.

Authors:  A P Geballe; R R Spaete; E S Mocarski
Journal:  Cell       Date:  1986-09-12       Impact factor: 41.582

5.  An RNA stem-loop structure directs hepatitis B virus genomic RNA encapsidation.

Authors:  J R Pollack; D Ganem
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

6.  Isolation and characterization of a hepatitis B virus endemic in herons.

Authors:  R Sprengel; E F Kaleta; H Will
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

7.  Comparative sequence analysis of duck and human hepatitis B virus genomes.

Authors:  R Sprengel; C Kuhn; H Will; H Schaller
Journal:  J Med Virol       Date:  1985-04       Impact factor: 2.327

8.  Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli.

Authors:  F Galibert; E Mandart; F Fitoussi; P Tiollais; P Charnay
Journal:  Nature       Date:  1979-10-25       Impact factor: 49.962

9.  Characterization of the cis-acting contributions to avian hepadnavirus RNA encapsidation.

Authors:  Kristin M Ostrow; Daniel D Loeb
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

10.  Sequence of the lacZ gene of Escherichia coli.

Authors:  A Kalnins; K Otto; U Rüther; B Müller-Hill
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

View more
  7 in total

1.  A high level of mutation tolerance in the multifunctional sequence encoding the RNA encapsidation signal of an avian hepatitis B virus and slow evolution rate revealed by in vivo infection.

Authors:  Bernadette Schmid; Christine Rösler; Michael Nassal
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

2.  Hepatitis B virus molecular biology and pathogenesis.

Authors:  R Jason Lamontagne; Sumedha Bagga; Michael J Bouchard
Journal:  Hepatoma Res       Date:  2016-07-01

Review 3.  Hepadnavirus Genome Replication and Persistence.

Authors:  Jianming Hu; Christoph Seeger
Journal:  Cold Spring Harb Perspect Med       Date:  2015-07-01       Impact factor: 6.915

4.  The interface between hepatitis B virus capsid proteins affects self-assembly, pregenomic RNA packaging, and reverse transcription.

Authors:  Zhenning Tan; Karolyn Pionek; Nuruddin Unchwaniwala; Megan L Maguire; Daniel D Loeb; Adam Zlotnick
Journal:  J Virol       Date:  2015-01-07       Impact factor: 5.103

5.  Genetically altering the thermodynamics and kinetics of hepatitis B virus capsid assembly has profound effects on virus replication in cell culture.

Authors:  Zhenning Tan; Megan L Maguire; Daniel D Loeb; Adam Zlotnick
Journal:  J Virol       Date:  2013-01-02       Impact factor: 5.103

6.  Distinct families of cis-acting RNA replication elements epsilon from hepatitis B viruses.

Authors:  Augustine Chen; Chris Brown
Journal:  RNA Biol       Date:  2012-02-01       Impact factor: 4.652

7.  Replication-competent infectious hepatitis B virus vectors carrying substantially sized transgenes by redesigned viral polymerase translation.

Authors:  Zihua Wang; Li Wu; Xin Cheng; Shizhu Liu; Baosheng Li; Haijun Li; Fubiao Kang; Junping Wang; Huan Xia; Caiyan Ping; Michael Nassal; Dianxing Sun
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.